# China NMPA Drug Inspection - Anhui Yishengyuan Traditional Chinese Medicine Pieces Technology Co., Ltd. - Stir-fried Atractylodes lancea (batch number 170401)

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/anhui-yishengyuan-traditional-chinese-medicine-pieces-technology-co-ltd/15c3a687-f460-4902-af91-08f4147c2a54/
Source feed: China

> China NMPA drug inspection for Anhui Yishengyuan Traditional Chinese Medicine Pieces Technology Co., Ltd. published May 30, 2018. Drug: Stir-fried Atractylodes lancea (batch number 170401). On May 30, 2018, the Henan Provincial Food and Drug Administration announced findings of substandard drugs from two manu

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Announcement from the Henan Provincial Food and Drug Administration Regarding Three Batches of Substandard Drugs (Issue No. 5, 2018)
- Company Name: Anhui Yishengyuan Traditional Chinese Medicine Pieces Technology Co., Ltd.
- Publication Date: 2018-05-30
- Drug Name: Stir-fried Atractylodes lancea (batch number 170401)
- Inspection Finding: The non-compliance was due to the content of the non-compliant item.
- Action Taken: Necessary risk control measures such as sealing up, seizing, and suspending sales will be implemented, and the units responsible for the source of the inspected goods will be investigated and dealt with in accordance with the law.
- Summary: On May 30, 2018, the Henan Provincial Food and Drug Administration announced findings of substandard drugs from two manufacturers. Anhui Yiyuantang Traditional Chinese Medicine Pieces Technology Co., Ltd. was cited for two batches of Stir-fried Atractylodes lancea. Batch number 170420 was found to be substandard due to excessive moisture content, while batch number 170401 failed due to insufficient overall content. Separately, Anhui Jiayou Traditional Chinese Medicine Pieces Co., Ltd.'s Acanthopanax senticosus (batch number 170803) was deemed substandard for its extractive levels. These determinations were made following testing by provincial drug inspection agencies, using the Chinese Pharmacopoeia 2015 Edition, Part I, as the regulatory benchmark. In response to these violations, the administration mandated immediate risk control actions. These measures include the sealing, seizing, and suspending of sales for all affected drug batches. Additionally, relevant regulatory departments were instructed to initiate legal investigations and impose penalties on the manufacturers responsible for the non-compliant products, ensuring adherence to national pharmaceutical quality standards.

Company: https://www.globalkeysolutions.net/companies/anhui-yishengyuan-traditional-chinese-medicine-pieces-technology-co-ltd/c2292c5b-5423-41d2-824e-557e75208bc9/